The naive question a smart friend would ask in early 2020 is simple: a company is literally named CRISPR Therapeutics — so what does it actually make? The short version, straight from its annual report, is that it does not yet sell anything. It is building gene-editing medicines, and the lead one is a treatment for inherited blood disorders.
In its Form 10-K filed February 12, 2020, CRISPR Therapeutics describes pursuing gene editing of stem cells, noting that the potential to genetically engineer these cells is large. Think of it like a word processor for DNA: CRISPR is the search-and-replace tool, and the company's bet is that you can edit a patient's own blood stem cells to fix the genetic typo behind diseases like sickle cell.
In plain terms, the modality works like this. Doctors collect a patient's hematopoietic (blood-forming) stem cells, edit them outside the body — ex vivo — and put them back. The edit is meant to switch a gene back on so the body makes a healthy form of hemoglobin. Because you are changing the cells themselves, the hope is a one-time treatment rather than a lifelong drug.
It is worth being honest about where this stands as of this writing. The 2019 10-K describes a company defined by candidates and a collaboration, not by sales. Gene editing in humans is early. The science is striking, but in 2020 it is still being proven in the clinic, and the filing reads like the document of a research-stage company — because that is what it is.
The EdgarBeast evidence index, which surfaces and normalizes SEC filings, lets you read a company's own description of its science before any press release dresses it up. CRISPR Therapeutics' own words in early 2020 are modest: a platform, a lead program in blood disorders, and a large but unproven potential. That is the honest starting line.